Participated · Series A · Jan 2024

Vita Health delivers clinically validated suicide-prevention care management via telehealth, and also offers teletherapy and psychiatry for broader behavioral health conditions. Its care pathways are based on the founding team’s clinical trials published in JAMA and The American Journal of Psychiatry and thousands of patient encounters. Those trials and encounters demonstrated reductions in suicide attempts by more than 60% and deaths by up to 80%. The company was founded by a consortium of suicide risk experts and behavioral health innovators and has expanded its mission to address the youth mental health crisis, including anxiety and depression. Vita Health is building relationships with health plans, provider partners, employers, colleges, and universities to expand access. The company plans to use new funding to support rapid nationwide expansion of its life-saving services for youth and adults.

Led · Equity · May 2022

uMotif offers a patient-facing platform that captures validated patient-generated data including e-consent, eCOA, ePRO, PROM and PREM for clinical and real-world studies. Its software is deployed in over 30 countries, including China and Japan, and is used by pharma, biotech, medtech and CRO clients. The company reports high engagement and data-capture rates in excess of 90% and says an immunology study reduced data-capture timelines by 33%. uMotif highlights patent-protected technology and solutions for pain, clinical outcome and symptom tracking. The company plans to expand internationally and grow its sales, marketing and service-delivery teams. Financially, uMotif recently secured a $25.5M financing to support global expansion and further technology development. uMotif offers a patient-facing app that captures self-reported data for treatments and drug trials, which feeds into a platform sold to life sciences companies to enable faster, decentralized clinical and real-world studies. The company’s platform is used in studies across 26 countries and more than 25 therapeutic areas, and its largest study enrolled over 13,000 participants tracking pain levels and weather (featured on the BBC and published in Nature). The shift away from centralized site-based studies has been accelerated by COVID-19, increasing demand for uMotif’s patient-centered data capture. Competitors are largely U.S.-based and include SnapIOT, Medable and Clinical Ink. Management says the new funding will rapidly accelerate product development and help customers implement patient-centered research designs to get therapies to patients faster. The company has previously raised funding and the latest round brings its total funding to £7.5M. uMotif offers a cloud-based software platform that provides patient-facing technology to capture real-world data (eCOA, ePRO, eConsent) for clinical research from early phase to post-marketing trials. The platform is device-agnostic and already in use by top pharma companies including AstraZeneca, Novartis and UCB across multiple therapeutic areas. Its client base spans Europe and North America and includes global pharma companies, academic medical centres and contract research organizations. Founded in 2012 by Bruce Hellman and Ben James and based in London, the company is expanding its product capabilities and geographic reach. In June 2018 uMotif raised £2.4m in funding to scale the team, build features such as new language integration, and expand into the Asia Pacific market.

Led · Equity · Mar 2019

Secura Bio is dedicated to the worldwide commercialization of significant oncology therapies for physicians and patients. The company is led by President and CEO Joseph M. Limber. It closed a $145M financing package comprised of equity and debt to support its commercial efforts. The financing included a $55M equity tranche and a $90M debt facility, with $50M of the debt initially funded and an additional $40M available. The round was backed by funds managed by Athyrium Capital Management and participation from Secura Bio's executive team. The founding executive team has a track record of launching or relaunching more than 20 therapeutic products and founding or managing companies that reached acquisition or IPO (Sequus, Praecis, Aclara, Gevo, Prometheus, Agarigen, Genoptix).

Led · Equity · Jul 2018

Agendia develops and markets genomic diagnostic products for oncology, including the MammaPrint 70-gene risk-of-recurrence test and the BluePrint molecular subtyping test, both on microarray technology, plus a new MammaPrint BluePrint test on NGS. Led by CEO Mark R. Straley and based in Irvine, CA and Amsterdam, the company also has a pipeline of additional genomic products in development. Agendia collaborates with pharmaceutical companies, cancer centers and academic groups to develop companion diagnostics. The company plans to use new financing to accelerate commercial expansion in the U.S. and international markets and to increase adoption of its sequencing-based MammaPrint BluePrint kit. It will invest in Big Data programs, including full-genome profiling trials FLEX (U.S.) and PRECiSE (Netherlands), and establish collaborative research programs with academic institutions to advance its precision oncology pipeline. Agendia develops and markets genomic-based cancer diagnostic products, principally the Symphony™ suite of breast cancer tests including MammaPrint and BluePrint. MammaPrint is FDA‑cleared and is described in the release as the company’s flagship, fastest‑growing, cost‑effective breast cancer recurrence assay; Symphony also includes TargetPrint and TheraPrint for molecular subtyping and therapy selection. The company was formed in 2003 as a spin‑out from the Netherlands Cancer Institute and is privately owned. In March 2014 Norgine Ventures led a €15 million debt financing to help accelerate Agendia’s commercial expansion in the US, Europe and Asia. Agendia operates a direct sales team in the US, the Netherlands, Italy, Germany, Switzerland and Austria, with a distributor network servicing the rest of the world. The company maintains a pipeline of genomic products and collaborates with pharmaceutical companies, leading cancer centres and academic groups on companion diagnostics and trials such as ISPY‑2 and MINDACT. Agendia develops and markets genomic-based diagnostic products to help support physicians with complex treatment decisions. Its breast cancer Symphony suite includes MammaPrint (an FDA-cleared IVDMIA breast cancer recurrence assay), BluePrint, TargetPrint and TheraPrint. The company recently launched the Symphony suite and plans to expand its commercialization. Agendia is also developing a personalized medicine pipeline and is preparing to launch ColoPrint, a recurrence test for stage II colon cancer prognosis and prediction. The company is led by CEO David Macdonald and is based in Boston, MA. It raised $65M in equity financing to support these commercialization and development efforts. Agendia develops molecular diagnostic tests for cancer, including MammaPrint, an in vitro diagnostic multivariate index assay (IVDMIA). The company plans to use the recent proceeds to accelerate commercialization of MammaPrint in the U.S. market. Agendia announced the closing of a $23m Series E financing to support that effort. The round included a lead investment from an undisclosed firm that provided approximately 50% of the funds, two independent entrepreneurs who invested $1m each, and additional capital from the company’s existing investor base. Dr. Bernhard Sixt, President and CEO, commented that the proceeds will be used to accelerate U.S. commercialization. The company is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

Led · Equity · Jan 2018

VillageMD operates more than 230 practices in 15 markets and focuses on value-based primary care delivered through physician-staffed clinics and Village Medical locations. The company expects to generate $1.3 billion in revenue this year, up from $217 million in 2017. Many VillageMD practices are co-located with Walgreens stores, and the partnership is central to its expansion plans. Walgreens' investment is intended to accelerate the rollout of hundreds of doctor-staffed Village Medical at Walgreens practices. VillageMD aims to open at least 600 such clinics in more than 30 U.S. markets by 2025 and 1,000 by 2027, with more than half in medically underserved communities. The company plans an initial public offering next year. VillageMD, through its subsidiary Village Medical, partners with physicians to provide tools, technology, operations, staffing support and industry relationships to deliver clinical care and reduce total cost of care. The Village Medical brand provides primary care at traditional free-standing clinics, Village Medical at Walgreens clinics, at home and via virtual visits. VillageMD and Village Medical have grown to include more than 2,800 physicians across nine markets, are responsible for approximately 600,000 lives and manage $4 billion in total medical spend in value-based contracts. The company plans to open 500 to 700 full-service primary care clinics co-located with Walgreens stores in more than 30 US markets over the next five years, with the intent to build several hundred more clinics and enter up to 20 additional US markets over time. Those clinics will be staffed by more than 3,600 primary care providers to be recruited by VillageMD, and the expansion is tied to a deepened partnership with Walgreens Boots Alliance. VillageMD provides tools, technology (including its docOS platform), operations, and staffing support to physicians and health systems to drive quality clinical results across patient populations. The company partners with more than 2,500 primary care physician groups, independent practice associations, and health systems. It manages $3 billion of total medical spend in value-based contracts. VillageMD operates under the Village Medical brand and also offers a Village Medical at Home service. Led by CEO and co-founder Tim Barry, the company plans to expand its primary care presence in existing and new markets and to enhance its docOS platform. The recent financing positions VillageMD to scale its brand and home-based offerings. VillageMD partners with primary care providers to lower costs and improve patient outcomes by supplying data analytics, physician-based care coordination, and on-the-ground support resources. The company says it now works with 2,500 primary care physician partners across six states. VillageMD plans to use the new funding to expand into more markets and invest in its technology platform. Founded in 2013, VillageMD was started by Tim Barry and Clive Fields; Tim Barry serves as CEO. Last February the company added Zeke Emanuel to its board of directors. Financially, the company has shown multi-year growth and emphasizes clinical and financial results achieved with partners. VillageMD partners with leading primary care providers, physician groups, IPAs, and health systems to support a primary care–led, value-oriented clinical model. The company provides tools, technology, and operational support designed to drive higher-quality clinical results, increase patient satisfaction, and lower costs. VillageMD brings health-plan relationships that reward primary care providers for practicing higher-quality, lower-cost medicine and relies on a proven operating model of people, processes, and technology. It currently partners with over 400 primary care providers across markets in Texas and Indiana. VillageMD is headquartered in Chicago, IL. The company plans to use new capital to accelerate national expansion into several new states across the Midwest, Northeast, and Southeast.